Clinical Trial Update: Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D [Phase 4]

View source ↗

Summary

Phase 4 clinical trial results describe transitioning patients with type 2 diabetes mellitus from a basal/bolus insulin regimen to a once-weekly subcutaneous se…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Basal insulin (basal insulin)
• semaglutide (semaglutide)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Type 2 Diabetes | Phase 4 | Status: COMPLETED | Results posted: 2024-07-29